Intensified chemo-immuno-radiotherapy with durvalumab (MEDI4736) for stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II study (PACIFIC BRAZIL)
Type of Study: Clinical Trial
Sponsor / Support: LACOG
Primary Objectives: The primary objective of this study is to determine the 12-month progression-free survival, defined as the proportion of patients alive and progression-free at month 12, estimated by the Kaplan Maier method.
Design: This is a prospective, non-randomized, open label, single arm, multi-institutional, phase 2 study.
Sample Size: 48 patients
Principal Investigator: William William
Countries LATAM: Brazil
LACOG 0217 – IRONMAN
LACOG 0218 – Hercules
LACOG 0415 – APA in Prostate Cancer
LACOG 0515 – Testicular Registry
LACOG 0519 – PEACE III
LACOG 0620 – ExBAT
LACOG 1518 – Bladder Cancer Registry
LACOG 1818 – Prostate Cancer Registry